#eli-lilly

#eli-lilly

From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities. On the other hand, it did experience a revenue shortfall in the fourth quarter.

Eli Lilly (NYSE:LLY) has quickly emerged as one of Wall Street's biggest winners, fueled by explosive demand for its new generation of weight-loss and diabetes treatments. The company's GLP-1 drugs, including Mounjaro and the newly approved Zepbound, have turned into blockbuster products, generating billions in sales and reshaping the pharmaceutical landscape. As a result, Eli Lilly's stock surged more than 50% year-to-date in 2024.

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, emphasizing the importance of medication access.

Eli Lilly is suing four telehealth companies for selling illegal copies of its weight-loss drug Zepbound, which is based on the active ingredient tirzepatide.

That's where being a savvy investor comes in. Being contrarian, you can pick up these hidden gems at a significant discount and profit all the way to the bank when their fortunes turn.